Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/39907
Title: Different faces of Nocardia infection in renal transplant recipients.
Authors: Brown F.;Yii M.;Kerr P.G. ;Polkinghorne K.R. ;Mulley W. ;Shrestha S.;Kanellis J.;Korman T. 
Institution: (Shrestha, Kanellis, Polkinghorne, Brown, Kerr, Mulley) Department of Nephrology, Monash Medical Centre, Department of Medicine, Monash University, Melbourne, VIC, Australia (Shrestha) Department of Internal Medicine, Nobel Medical College, Teaching Hospital, TUTH, Maharajganj, Kathmandu, Biratnagar 00977, Nepal (Kanellis, Polkinghorne, Kerr, Mulley) Department of Medicine, Monash University, Melbourne, VIC, Australia (Korman) Department of Infectious Disease and Microbiology, Monash Medical Centre, Melbourne, VIC, Australia (Yii) Department of Vascular Surgery, Monash Medical Centre, Melbourne, VIC, Australia
Issue Date: 11-Feb-2016
Copyright year: 2016
Publisher: Blackwell Publishing (E-mail: info@asia.blackpublishing.com.au)
Place of publication: Australia
Publication information: Nephrology. 21 (3) (pp 254-260), 2016. Date of Publication: 01 Mar 2016.
Journal: Nephrology
Abstract: Aim Nocardia infections are an uncommon but important cause of morbidity and mortality in renal transplant recipients. The present study was carried out to determine the spectrum of Nocardia infections in a renal transplant centre in Australia. Methods A retrospective chart analysis of all renal transplants performed from 2008 to 2014 was conducted to identify cases of culture proven Nocardia infection. The clinical course for each patient with nocardiosis was examined. Results Four of the 543 renal transplants patients developed Nocardia infection within 2 to 13 months post-transplant. All patients were judged at high immunological risk of rejection pre-transplant and had received multiple sessions of plasmaphoeresis and intravenous immunoglobulin before the onset of the infection. Two patients presented with pulmonary nocardiosis and two with cerebral abscesses. One case of pulmonary nocardiosis was complicated by pulmonary aspergillosis and the other by cytomegalovirus pneumonia. All four patients improved with combination antibiotic therapy guided by drug susceptibility testing. At the time of Nocardia infection all four patients were receiving primary prophylaxis with trimethoprim/sulphamethoxazole (TMP/SMX) 160/800 mg, twice weekly. Conclusion Plasmaphoeresis may be risk factor for Nocardia infection and need further study. Nocardia infection may coexist with other opportunistic infections. Identification of the Nocardia species and drug susceptibility testing is essential in guiding the effective management of patients with Nocardia. Intermittent TMP-SMX (one double strength tablet, twice a week) appears insufficient to prevent Nocardia infection in renal transplant recipients.Copyright © 2015 Asian Pacific Society of Nephrology.
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/nep.12585
PubMed URL: 26820918 [http://www.ncbi.nlm.nih.gov/pubmed/?term=26820918]
ISSN: 1320-5358
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/39907
Type: Article
Appears in Collections:Articles

Show full item record

Page view(s)

40
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.